The postphlebitic syndrome is a result of previous deep vein thrombosis and presents with oedema, pain, induration, pigmentation and ulceration. Extravascular deposition of fibrin is associated with reduced fibrinolytic activity in these patients. In a double-blind crossover study there was evidence of benefit from stanozolol which enhanced fibrinolytic activity. No side effects of any consequence were noted with a dosage of 5 mg twice per day.
BrowseNLBurnandKG. In Venous Problems: BerganJYaoJ eds. Chicago: Year Book. Medical Publishers, 1978: 395–404.
2.
BrowseNLGrayLJarrettPEMMorlandM.Blood and vein wall fibrinolytic activity in health and vascular disease. Br Med J1977; 1: 478–481.
3.
JarretPEMBurnandKGMorlandMBrowseNL. Fibrinolysis and fat necrosis in the lower leg. Br J Surg (abstract)1976; 63: 157.
4.
BurnandKGLeaTMO'DonellTBrowseNL. Relationship between postphlebitic changes in the deep vein and results of surgical treatment of venous ulcers. Lancet1976; 1: 936–938.
5.
BrowseNLJarrettPEMMorlandMBurnandK.Treatment of liposclerosis of the leg by fibrinolytic enhancement: a preliminary report. Br Med J1977; 2: 434–435.
6.
BurnandKClemensonGMorlandMJarrettPEMBrowseNL. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic stockings. Br Med J1980; 280: 7–12.
7.
JarrettPEMMorlandMBrowseNL. The complications of stanozolol and their clinical management. In: Progress in Chemical Fibrinolysis and Thrombolysis, Vol. IV, DavidsonJF ed. Edinburgh: Churchill Livingstone, 1979: 317–321.
